Abstract
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) in which dysregulation of the complement cascade leads to microvascular thrombi, microangiopathic hemolytic anemia, thrombocytopenia, and damage to the kidneys and/or other end organs. Although it is considered a rare disease, a number of presentations and posters at the recent Kidney Week conference provided new insights into aHUS management, and gave a glimpse of how our evolving understanding of complement regulation and dysregulation, and the potential role of complement in a constellation of interconnected diseases and conditions, may eventually help us offer more personalized and comprehensive patient care.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call